What comes after the drugs

For most of the past thirty years, the options were surgery and advice. Then came GLP-1 medications, which amplify a satiety signal the gut already produces, and which do so effectively.C-IV-07

What these medications do not do is discriminate. The same lever is pulled for everyone, regardless of which part of their physiology is behaving unusually: how quickly the stomach empties, how the duodenum is signaling, or how much of their appetite is reward rather than hunger.

The first part of the small intestine does more signaling than its size would suggest, and in metabolic disease its lining behaves abnormally. Duodenal mucosal resurfacing is an endoscopic treatment that resurfaces that lining, on the theory that the abnormal surface is part of the problem rather than a consequence of it.C-IV-16

Taken together, the picture is a plausible idea, an active research program, and a negative primary result that has to be explained before anyone should be confident about the treatment.

Most ghrelin is produced in the stomach, and ESG does not lower it.C-IV-05 To act on ghrelin directly, you would have to act on the tissue that produces it.

Gastric mucosal ablation does that directly: it selectively devitalizes the ghrelin-producing lining. The procedure is investigational, which is the word an international expert consensus uses for it. The first-in-human trial performed it as a separate step before a gastroplasty.C-IV-06

That is where it stands: a first-in-human stage, a single small trial, and a mechanism that makes sense. Everself doesn't offer it.

The idea underneath all of this is that obesity is not one condition with one lever. Two people at the same weight can have arrived there by different routes (one with a stomach that empties quickly, another with reward signaling that overrides fullness, a third with a duodenum that behaves abnormally), and the treatment that helps one may do little for the other.

This is a framework rather than a finding.C-IV-17 It is argued for in the literature, and it is intuitive to anyone who treats these patients. No randomized trial has yet shown that matching a treatment to a phenotype produces better outcomes than standard care.

Nothing on this page is a treatment you can have. Two of the three are first-in-human or have a failed primary endpoint behind them, and the third is a way of thinking that has not been tested against the alternative.

What the page is useful for is calibration. If someone offers you a procedure aimed at your duodenum, or a test that sorts you into a phenotype and prescribes accordingly, the current state of the evidence is the one set out above.

The options that exist today are covered in medication vs. procedure.